Letter

European register of patients with sickle cell disease treated with hydroxyurea is being set up

BMJ 1998; 317 doi: 10.1136/bmj.317.7157.541a (Published 22 August 1998)
Cite this as: BMJ 1998;317:541.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Sally C Davies, Director of research and development,
  2. Marilyn Roberts-Harwood, Research registrar
  1. NHS Executive North Thames Regional Office, London W2 3QR
  2. Department of Haematology, Central Middlesex Hospital, London NW10 7NS

    EDITOR—In 1995 Charache et al showed conclusively in the United States that hydroxyurea ameliorates the clinical consequences of sickle cell disease in most patients.1There is no biological reason to expect greatly different results in Britain. Moreover, there has not been any serious discussion at any meetings of European or North American experts that has been in support of repeating the study. Doing so is not warranted from either the research or cost perspectives.

    We were therefore surprised to read the editorial by Olujohungbe …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular